Drug Pipeline

GV20-0251 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
1
Recruiting
3
Top Sponsors
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-09 NCT07623642
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in…		 Primary endpoint(s) modified
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-06-03 NCT07623642 A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in… Phase 2 Not Yet Recruiting
Active Studies by Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT07623642 A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in… Uterine Cervical Neoplasms Not Yet Recruiting
Phase 1/2
NCT07307053 Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) Rare Malignant Neoplasm Not Yet Recruiting
Phase 1
NCT07457281 GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous… Head and Neck Squamous Cell Carcinoma HNSCC Recruiting
Sponsors Running GV20-0251 Trials
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) West China Hospital (1) GV20 Therapeutics (1)
Disease Areas
Head & Neck Cancer (1) Non-Small Cell Lung Cancer (NSCLC) (1) Small Cell Lung Cancer (1) Lung Cancer (1) Breast Cancer (1) Colorectal Cancer (1) Pancreatic Cancer (1) Bladder Cancer (1) Cervical Cancer (1) Cholangiocarcinoma (1)
Get alerts when GV20-0251 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free